Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03932786 · ClinicalTrials.gov registry record

Studying Health Outcomes After Treatment in Patients With Retinoblastoma

A clinical trial of Cancer Survivor and Retinoblastoma, sponsored by Vanderbilt-Ingram Cancer Center.

Recruiting
Registry status
900
Enrollment target
11
Study locations

NCT03932786: Recruiting study of Cancer Survivor and Retinoblastoma, sponsored by Vanderbilt-Ingram Cancer Center.

NCT03932786 is a study of Cancer Survivor and Retinoblastoma that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 900 participants, above the 230-participant average among 25 other Cancer Survivor trials with a reported enrollment target (291% higher). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03932786, a study of Cancer Survivor and Retinoblastoma, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.

RECRUITING
Registry status
900 participants
Enrollment target
11
Study locations

Study Summary

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Biospecimen collection
  • OTHER Questionnaire administration
  • OTHER Quality of life assessment
  • OTHER Vision assessment

Study Locations (11)

Illinois

  • Lurie Children's Hospital - Chicago
  • University of Illinois, Chicago - Chicago

Texas

  • MD Anderson Cancer Center - Houston
  • Texas Childeren's Hospital - Houston

Minnesota

  • University of Minnesoa - Minneapolis

Missouri

  • Washington School of Medicine at St. Louis - St Louis

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Tennessee

  • Vanderbilt-Ingram Cancer Center - Nashville

Wisconsin

  • Children's Hospital of Wisconsin - Milwaukee

Trial Details

FieldValue
Enrollment Target 900 participants
Start Date 2019-01-24
Est. Completion 2031-01
Vanderbilt-Ingram Cancer Center

189 total trials

What NCT03932786 shows while recruiting

NCT03932786 is an observational study that tracks outcomes without assigning an intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 230-participant average among 25 other Cancer Survivor trials with a reported enrollment target (291% higher).

The record links to 5 conditions, with Cancer Survivor appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT03932786 lists 11 locations in 9 states (Illinois, Texas, Minnesota).

Frequently Asked Questions

What is clinical trial NCT03932786 about?

NCT03932786 is a clinical study titled "Studying Health Outcomes After Treatment in Patients With Retinoblastoma". This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, ident...

What is the current status of trial NCT03932786?

This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2019-01-24. Estimated completion is 2031-01.

What conditions does trial NCT03932786 study?

This clinical trial studies the following conditions: Cancer Survivor, Retinoblastoma, Unilateral Retinoblastoma, Intraocular Retinoblastoma, Biological Sibling.

What interventions are being tested in trial NCT03932786?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Biospecimen collection (PROCEDURE), Questionnaire administration (OTHER), Quality of life assessment (OTHER), Vision assessment (OTHER).

Who is sponsoring clinical trial NCT03932786?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03932786 being conducted?

This trial has 11 study locations across Illinois, Minnesota, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Survivor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03932786's enrollment target sits among peer trials

900 2nd of 25 the highest of 25 other Cancer Survivor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer Survivor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02352116 · 900 participants · NA

    Evaluation of Post-PACU Pain Management in Pediatric Surgery

  • NCT02414347 · 900 participants

    F 18 T807 Tau PET Imaging of Alzheimer's Disease

  • NCT02670408 · 900 participants

    Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation

  • NCT02960022 · 900 participants · Phase 2

    A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03932786, the US trial registry maintained by the National Library of Medicine. NCT03932786 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.